Cutaneous Fungal Infections in the Oncology Patient
Tóm tắt
There are two main types of fungal infections in the oncology patient: primary cutaneous fungal infections and cutaneous manifestations of fungemia. The main risk factor for all types of fungal infections in the oncology patient is prolonged and severe neutropenia; this is especially true for disseminated fungal infections. Severe neutropenia occurs most often in leukemia and lymphoma patients exposed to high-dose chemotherapy. Fungal infections in cancer patients can be further divided into five groups: (i) superficial dermatophyte infections with little potential for dissemination; (ii) superficial candidiasis; (iii) opportunistic fungal skin infections with distinct potential for dissemination; (iv) fungal sinusitis with cutaneous extension; and (v) cutaneous manifestations of disseminated fungal infections. In the oncology population, dermatophyte infections (i) and superficial candidiasis (ii) have similar presentations to those seen in the immunocompetent host. Primary cutaneous mold infections (iii) are especially caused by Aspergillus, Fusarium, Mucor, and Rhizopus spp. These infections may invade deeper tissues and cause disseminated fungal infections in the neutropenic host. Primary cutaneous mold infections are treated with systemic antifungal therapy and sometimes with debridement. The role of debridement in the severely neutropenic patient is unclear. In some patients with an invasive fungal sinusitis (iv) there may be direct extension to the overlying skin, causing a fungal cellulitis of the face. Aspergillus, Rhizopus, and Mucor spp. are the most common causes. We also describe the cutaneous manifestations of disseminated fungal infections (v). These infections usually occur in the setting of prolonged neutropenia. The most common causes are Candida, Aspergillus, and Fusarium spp. Therapy is with systemic antifungal therapy. The relative efficacies of amphotericin B, fluconazole, itraconazole, voriconazole, and caspofungin are discussed. Recovery from disseminated fungal infections is unlikely, however, unless the patient’s neutropenia resolves.
Tài liệu tham khảo
Brown AE. Overview of fungal infections in cancer patients. Semin Oncol. 1990; 17 (3): 2–5
Morrison VA, Haake RJ, Weisdorf DJ. The spectrum of non-Candida fungal infections following bone marrow transplantation. Medicine. 1993; 72 (2): 78–89
Nosari A, Oreste P, Cairoli R, et al. Invasive aspergillosis in hematological malignancies: clinical findings and management for intensive chemotherapy completion. Am J Hematol. 2001; 68: 231–6
Stein DK, Sugar AM. Fungal infections in the immunocompromised host. Diagn Microbiol Infect Dis. 1989; 12: 221S–8S
Grossman ME. Cutaneous manifestations of infection in the immunocompromised host. Baltimore (MD): Williams & Wilkins, 1995: 62–7
Wolfson JS, Sober AJ, Rubin RH. Dermatologic manifestations of infections in immunocompromised patients. Medicine. 1985; 64 (2): 115–33
Bodey GP, Boktour M, Mays S, et al. Skin lesions associated with Fusarium infection. J Am Acad Dermatol. 2002; 47: 659–66
Nucci M, Anaissie E. Cutaneous infections by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management. Clin Infect Dis. 2002; 35: 909–20
Tosti A, Piraccini BM, Lorenzi S. Onychomycosis caused by nondermatophyte molds: clinical features and response to treatment of 59 cases. J Am Acad Dermatol. 2000; 42 (2): 217–24
Grossman ME. Cutaneous manifestations of infection in the immunocompromised host. Baltimore (MD): Williams & Wilkins, 1995: 188
Alto MD, Miller J, Townsend T, et al. Primary cutaneous aspergillosis associated with Hickman intravenous catheters. N Engl J Med. 1987; 317: 1105–8
Walmsley S, Devi S, King S, et al. Invasive Aspergillus infections in a pediatric hospital: a ten year review. Pediatr Infect Dis J. 1993; 12: 673–82
McCarty JM, Flam MS, Pullen G, et al. Outbreak of primary cutaneous aspergillosis related to intravenous arm boards. J Pediatr. 1986; 108: 721–4
Abbasi S, Shenep JL, Hughes WT, et al. Aspergillosis in children with cancer: a 34 year experience. Clin Infect Dis. 1999; 29: 1210–9
Sheldon DL, Johnson WC. Cutaneous mucormycosis: two documented cases of suspected nosocomial cause. JAMA. 1978; 241: 1032–4
Gartenberg G, Bottone EJ, Keusch GT, et al. Hospital-acquired mucormycosis (Rhizopus rhizopodoformis) of skin and subcutaneous tissue. N Engl J Med. 1978; 299 (20): 1115–8
Hammond DE, Winkelmann RK. Cutaneous phycomycosis: report of three cases with identification of Rhizopus. Arch Dermatol. 1979; 115: 990–2
Everett ED, Pearson S, Rogers W. Rhizopus surgical wound infection associated with elasticized adhesive tape dressings. Arch Surg. 1979; 114: 738–9
Wirth F, Perry R, Eskenazi A, et al. Cutaneous mucormycosis with subsequent visceral dissemination in a child with neutropenia. J Am Acad Dermatol. 1996; 35: 336–41
Weitzman I. Saprophytic molds as agents of cutaneous and subcutaneous infection in the immunocompromised host. Arch Dermatol. 1986; 122: 1161–8
Boutati E, Anaissie E. Fusarium, a significant emerging pathogen in patients with hematologic malignancy. Blood. 1997; 3: 999–1008
Iwen PC, Rupp ME, Hinrichs SH. Invasive mold sinusitis: 17 cases in immunocompromised patients and review of the literature. Clin Infect Dis. 1997; 24: 1178–84
de Shazo RD, O’Brien M, Chapin K, et al. A new classification and diagnostic criteria for invasive fungal sinusitis. Arch Otolaryngol Head Neck Surg. 1997; 123: 1181–8
Mandell GL, Bennett JE, Dolin R. Principles and practice of infectious disease. Philadelphia (PA): Churchill Livingstone, 2000: 2679–2687
Ferry AP, Abedi S. Diagnosis and management of rhino-orbital mucormycosis. Ophthalmology. 1983; 90: 1096–104
Moss ALH. Rhinocerebral mucormycosis. Ann Plast Surg. 1982; 9 (5): 431–5
Howells RC, Ramadan HH. Usefulness of computed tomography and magnetic resonance in fulminant invasive fungal rhinosinusitis. Am J Rhinol. 2001; 15 (4): 255–61
Del Gaudio JM, Swain RE, Kingdom TT, et al. Computed tomographic findings in patients with invasive fungal sinusitis. Arch Otolaryngol Head Neck Surg. 2003; 129 (2): 236–40
Dignani MC, Anaissie E. Human fusariosis. Clin Microbiol Infect. 2004; 10 Suppl. 1: 67–75
Rolston K. Overview of systemic fungal infections. Oncology (Williston Park). 2001 Nov; 15 (11 Suppl. 9): 11–4
Klimowski LL, Rotstein C, Cummings KM. Incidence of nosocomial aspergillosis in patients with leukemia over a twenty year period. Infect Control Hosp Epidemiol. 1989; 10: 299–305
Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin Microbiol Rev. 2005; 18: 44–69
Pagano L, Antinori A, Ammassari A, et al. Retrospective study of candidemia in patients with hematologic malignancies: clinical features, risk factors and outcome of 76 episodes. Fur J Hematol. 1999; 63 (2): 77–85
Bodey GP, Luna M. Skin lesions associated with disseminated candidiasis. JAMA. 1979; 229: 1466–8
Grossman ME, Silvers DN, Walther RR. Cutaneous manifestations of disseminated candidiasis. J Am Acad Dermatol. 1980; 2: 111–6
Meyer PD, Kaplan MH, Ong M, et al. Cutaneous lesions in disseminated mucormycosis. JAMA. 1973; 225 (7): 732–8
Myskowski PL, Brown AE, Dinsmore R, et al. Mucormycosis following bone marrow transplantation. J Am Acad Dermatol. 1983; 9: 111–5
Kramer BS, Hernandez AD, Reddick RL, et al. Cutaneous infarction: manifestation of disseminated mucormycosis. Arch Dermatol. 1977; 113: 1075–6
Mandell GL, Bennett JE, Dolin R. Principles and practice of infectious disease. Philadelphia (PA): Churchill Livingstone, 2000: 2708
Grossman ME. Cutaneous manifestations of infection in the immunocompromised host. Baltimore (MA): Williams & Wilkins, 1995: 16
Grossman ME. Cutaneous manifestations of infection in the immunocompromised host. Baltimore (MA): Williams & Wilkins, 1995: 58
Walsh TJ. Trichosporonosis. Infect Dis Clin North Am. 1989; 3: 43–5
Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis: Infectious Diseases Society of America. Clin Infect Dis. 2004 Jan 15; 38 (2): 161–89
Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus: Infectious Diseases Society of America. Clin Infect Dis. 2000; 30 (4): 696–709
Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease: Infectious Diseases Society of America. Clin Infect Dis. 2000; 30 (4): 710–8
Bodey GP. Candidiasis in cancer patients. In: Bodey GP, editor. Candidiasis: a growing concern. Am J Med 1984; 77 (4D): 13–9
Goodrich JM, Reed E, Mori M, et al. Clinical factors and analysis of risk factors for invasive candidal infection after marrow-transplantation. J Infect Dis. 1991; 164: 731–40
Anaissie E, White M, Uzon O, et al. Amphotericin B lipid complex (ABLC) versus amphotericin B for treatment of hematogenous and invasive candidiasis: a prospective, randomized, multicenter trial [abstract]. Program and abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1995: 330
Kontoyiannis DP, Bodey GP, Mantzoros CS. Fluconazole vs amphotericin B for the management of candidaemia in adults: a meta-analysis. Mycoses. 2001; 44: 125–35
Rex JH, Pappas PG, Karchmer AW, et al. A randomized and blinded multicenter trial of high-dose Fuconazole (F) + placebo (P) vs F + amphotericin B (A) as treatment of candidemia in non-neutropenic patients [abstract no. J-681 a]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Sep 22–25; Chicago (IL), 378
Mora-Duarte J, Betts R, Coleman R, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2003; 347 (25): 2020–9
Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002; 347 (6): 408–15
Ellis M, Spence D, DePauw B, et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis. 1998; 27: 1406–12
Letscher-Bru V, Herbrecht R. Caspofungin: the first representative of a new antifungal class. J Antimicrob Chemother. 2003; 51: 513–21
Baddley JW, Pappas PG. Antifungal combination therapy: clinical potential. Drugs 2005; 65 (11): 1461–80
Antoniadou A, Kontoyiannis DP. Status of combination therapy for refractory mycoses. Curr Opin Infect Dis. 2003; 16: 539–45
Gupta SK, Sarosis GA. Cryptococcal meningitis. Curr Treat Options Infect Dis. 2002; 4: 403–511
Larsen RA, Bozzette SA, Jones BE, et al. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis. 1994; 19: 741–5
Anaissie E, Gokaslan A, Hachem R, et al. Azole therapy for trichosporonosis: clinical evaluation of eight patients, experimental therapy of murine infection, and review of the literature. Clin Infect Dis. 1992; 15: 781–7